Chemical and Structural Aspects of Ebola Virus Entry Inhibitors

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The Ebolaviruses are members of the family Filoviridae ("filoviruses") and cause severe hemhorragic fever with human case fatality rates as high as 90%. Infection requires attachment of the viral particle to cells and triggering of membrane fusion between the host and viral membranes, a process that occurs in the host endosome and is facilitated by the envelope glycoprotein (GP). One potential strategy for therapeutic intervention is the development of agents (antibodies, peptides, and small molecules) that can interfere with viral entry aspects such as attachment, uptake, priming, or membrane fusion. This paper highlights recent developments in the discovery and evaluation of therapeutic entry inhibitors and identifies opportunities moving forward.

Original languageEnglish (US)
Pages (from-to)42-52
Number of pages11
JournalACS Infectious Diseases
Volume1
Issue number1
DOIs
StatePublished - Jan 8 2015

Fingerprint

Ebolavirus
Virus Internalization
Membrane Fusion
Filoviridae
Endosomes
Virion
Glycoproteins
Fever
Cell Membrane
Peptides
Membranes
Mortality
Antibodies
Therapeutics
Infection

Keywords

  • Ebola virus
  • envelope glycoprotein
  • viral entry
  • viral hemhorragic fever

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Chemical and Structural Aspects of Ebola Virus Entry Inhibitors. / Nyakatura, Elisabeth K.; Frei, Julia C.; Lai, Jonathan R.

In: ACS Infectious Diseases, Vol. 1, No. 1, 08.01.2015, p. 42-52.

Research output: Contribution to journalArticle

@article{f6d469b9ce3143f698fd1228ab5e41e0,
title = "Chemical and Structural Aspects of Ebola Virus Entry Inhibitors",
abstract = "The Ebolaviruses are members of the family Filoviridae ({"}filoviruses{"}) and cause severe hemhorragic fever with human case fatality rates as high as 90{\%}. Infection requires attachment of the viral particle to cells and triggering of membrane fusion between the host and viral membranes, a process that occurs in the host endosome and is facilitated by the envelope glycoprotein (GP). One potential strategy for therapeutic intervention is the development of agents (antibodies, peptides, and small molecules) that can interfere with viral entry aspects such as attachment, uptake, priming, or membrane fusion. This paper highlights recent developments in the discovery and evaluation of therapeutic entry inhibitors and identifies opportunities moving forward.",
keywords = "Ebola virus, envelope glycoprotein, viral entry, viral hemhorragic fever",
author = "Nyakatura, {Elisabeth K.} and Frei, {Julia C.} and Lai, {Jonathan R.}",
year = "2015",
month = "1",
day = "8",
doi = "10.1021/id500025n",
language = "English (US)",
volume = "1",
pages = "42--52",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Chemical and Structural Aspects of Ebola Virus Entry Inhibitors

AU - Nyakatura, Elisabeth K.

AU - Frei, Julia C.

AU - Lai, Jonathan R.

PY - 2015/1/8

Y1 - 2015/1/8

N2 - The Ebolaviruses are members of the family Filoviridae ("filoviruses") and cause severe hemhorragic fever with human case fatality rates as high as 90%. Infection requires attachment of the viral particle to cells and triggering of membrane fusion between the host and viral membranes, a process that occurs in the host endosome and is facilitated by the envelope glycoprotein (GP). One potential strategy for therapeutic intervention is the development of agents (antibodies, peptides, and small molecules) that can interfere with viral entry aspects such as attachment, uptake, priming, or membrane fusion. This paper highlights recent developments in the discovery and evaluation of therapeutic entry inhibitors and identifies opportunities moving forward.

AB - The Ebolaviruses are members of the family Filoviridae ("filoviruses") and cause severe hemhorragic fever with human case fatality rates as high as 90%. Infection requires attachment of the viral particle to cells and triggering of membrane fusion between the host and viral membranes, a process that occurs in the host endosome and is facilitated by the envelope glycoprotein (GP). One potential strategy for therapeutic intervention is the development of agents (antibodies, peptides, and small molecules) that can interfere with viral entry aspects such as attachment, uptake, priming, or membrane fusion. This paper highlights recent developments in the discovery and evaluation of therapeutic entry inhibitors and identifies opportunities moving forward.

KW - Ebola virus

KW - envelope glycoprotein

KW - viral entry

KW - viral hemhorragic fever

UR - http://www.scopus.com/inward/record.url?scp=84969217544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969217544&partnerID=8YFLogxK

U2 - 10.1021/id500025n

DO - 10.1021/id500025n

M3 - Article

VL - 1

SP - 42

EP - 52

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

IS - 1

ER -